The Vasomotor Response to Dopamine Is Altered in the Rat Model of L-dopa-Induced Dyskinesia

Samuel Booth, BSc,1,2† Abdullah Ramadan, MS,1,2† Dali Zhang, PhD,1,2† Lingling Lu, PhD,2,3 Gilbert Kirouac, PhD,4 Michael F. Jackson, PhD,2,3 Chris Anderson, PhD,2,3 and Ji Hyun Ko, PhD1,2*

1Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Manitoba, Canada
2Kleyson Institute for Advanced Medicine, Health Science Centre, Winnipeg, Manitoba, Canada
3Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, Manitoba, Canada
4Department of Oral Biology, University of Manitoba, Winnipeg, Manitoba, Canada

ABSTRACT: Background: Levodopa (L-dopa) is the frontline treatment for motor symptoms of Parkinson’s disease. However, prolonged use of L-dopa results in a motor complication known as levodopa-induced dyskinesia (LID) in ~50% of patients over 5 years.

Objectives: We investigated neurovascular abnormalities in a rat model of LID by examining changes in angiogenesis and dopamine-dependent vessel diameter changes.

Methods: Differences in striatal and nigral angiogenesis in a parkinsonian rat model (6-OHDA lesion) treated with 2 doses of L-dopa (saline, 2, and 10 mg/kg/day subcutaneous L-dopa treatment for 22 days) by 5-bromo-2′-deoxyuridine (BrdU)-RECA1 co-immunofluorescence. Difference in the vasomotor response to dopamine was examined with 2-photon laser scanning microscopy and Dodt gradient imaging.

Results: We found that the 10 mg/kg L-dopa dosing regimen induced LID in all animals (n = 5) and induced significant angiogenesis in the striatum and substantia nigra. In contrast, the 2 mg/kg treatment induced LID in 6 out of 12 rats and led to linearly increasing LID severity over the 22-day treatment period, making this a promising model for studying LID progression longitudinally. However, no significantly different level of angiogenesis was observed between LID versus non-LID animals. Dopamine-induced vasodilatory responses were exaggerated only in rats that show LID-like signs compared to the rest of groups. Additionally, in juvenile rats, we showed that DA-induced vasodilation is preceded by increased Ca2+ release in the adjacent astrocytes.

Conclusion: This finding supports that astrocytic dopamine signaling controls striatal blood flow bidirectionally, and the balance is altered in LID. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Key Words: Parkinson’s disease; blood flow; dyskinesia; dopamine

Introduction

Levodopa (L-dopa) is the gold standard treatment for Parkinson’s disease (PD). However, with years of L-dopa treatment, patients variably develop motor complications associated with peak L-dopa dose termed L-dopa-induced dyskinesia (LID). LID patients are distinguished from stable L-dopa responders by large increases in extracellular dopamine at peak-dose of L-dopa, which is normalized off medication. This increase in dopamine release at peak plasma concentration is also observed in animal models of LID,2,3 and animal studies indicated that presynaptic mechanisms of dopamine release are disrupted in LID.4

Neurovascular abnormalities have been associated with LID in both human subjects and rat models,
including angiogenesis, blood–brain barrier defects, and acute increases in blood flow at peak L-dopa dose. In the 6-OHDA lesioned rat model of LID, chronically L-dopa-treated animals showed increased angiogenesis in the putamen, globus pallidus, and substantia nigra (SN), which was accompanied by evidence of blood–brain barrier dysfunction. Angiogenesis may contribute to LID by allowing dysregulated transmission of L-dopa across the blood–brain barrier in the striatum, exacerbating the large transient flux of synaptic dopamine that is characteristic of LID. However, blood–brain barrier deficiencies are independently a hallmark of neurodegenerative diseases including PD. It is therefore unknown whether angiogenesis is necessary for LID and to what extent angiogenesis distinguishes LID subjects from stable L-dopa responders. An acute increase in blood flow in the striatum has been observed in LID subjects at peak L-dopa dose, which is normalized when L-dopa is withdrawn and is independent of glucose metabolism. In normal conditions, regional cerebral blood flow is regulated by local synaptic activity through communication between astrocytes, neurons, and vascular smooth muscle in a process known as neurovascular coupling. These data indicate the neurovascular coupling response is dysregulated in LID. Astrocytes play a key role in the neurovascular coupling response, however, the role of astrocytic changes in cerebral blood flow regulation in LID has not been characterized.

Previously, stimulation of dopaminergic receptors on astrocytes has been shown to induce vessel diameter changes, indicating dopaminergic signaling is an important aspect of the neurovascular coupling response. Dopaminergic signaling can induce astrocyte-mediated vasodilation and vasoconstriction, indicating bimodal mode of action. Given that there is astrocytic dysfunction in LID, and astrocytes are an important part of the neurovascular coupling response, we hypothesized that the neurovascular uncoupling observed may be induced by a change in the astrocytic response to dopaminergic stimulation.

We used a rat model of LID to investigate inter-subject differences in striatal angiogenesis. For this purpose, we used both a high dose of L-dopa that induced severe dyskinesia in all animals, as well as a low L-dopa dose that induced dyskinesia only in a portion of the treated animals. We also used ex vivo imaging to demonstrate that an increase in vasodilation differentiates LID animals from non-LID animals. Additionally, in juvenile animals, we found that astrocytic calcium signaling dictates the subsequent vasomotor response to dopamine in adjacent astrocytes.

**Materials and Methods**

**Animal Model**

Based on the previous literature on LID rat model studies, we investigated 84 female Sprague–Dawley rats, housed in a 12-hour light/dark cycle in pairs with access to food and water ad libitum. All experiments were approved by the University of Manitoba committee on animal care in accordance with Canadian Council on Animal Care guidelines. Sixty-four animals underwent intracranial injection with 6-OHDA to produce a unilateral dopamine denervating lesion (for details, see Supplementary Methods).

**Experimental Design**

Supplementary Table S1 shows the number of animals in each group for each experiment. To examine the angiogenesis and confirm dopaminergic lesion in LID animal model, 22 animals (weighing 140–160 grams) were used for immunohistochemical analysis using BrdU-RECA1 co-immunofluorescence in confocal microscopy. Twelve animals received 2 mg/kg L-dopa, 5 animals received 10 mg/kg L-dopa, and 5 animals received an equivalent volume of isotonic saline for 22 days. 5-Bromo-2-deoxyuridine (BrdU) injection took place in 2 5-day sessions at days 4–8 and days 14–18 of treatment. At the end of experiments, animals were sacrificed via perfusion and collecting brain tissue. Details on the number of animals per group, daily treatment, immunohistochemistry can be found in the Supplementary Materials.

To examine the dopamine (DA)-induced vasomotor response in LID animal model, 42 rats (weighing 140–160 grams) were investigated using 2-photon laser scanning microscopy (TPLSM). Thirty-two 6-OHDA lesioned animals were administered 2 mg/kg L-dopa for 22 days. Five 6-OHDA lesioned animals were treated with an equivalent volume of isotonic saline as a drug naïve control group, and 5 non-6-OHDA lesioned animals were used as a wild-type control. On day +23, 1 day after the final L-dopa injection in LID and non-LID or saline, the animals were decapitated for brain slice preparation and Dodt gradient contrast imaging. The decapitation was obtained without anesthesia because anesthetic agents such as isoflurane affect DA activity, astrocytic Ca2+ activity, and vasomotor response.

To examine the relationship between astrocytic Ca2+ and vasomotor responses to DA, an additional 20 rats (21–28 postnatal days) were investigated using TPLSM. Younger rats were used for the examination of extracellular calcium dynamics, because older animal brains did not survive dye incubation. These rats were decapitated in the same manner as described above. All
analysis was performed by raters blind to the sample condition.

Behavioral Tests
After recovering from lesioning, animals were screened for hemi-parkinsonian-like behaviors using cylinder test as described elsewhere.24 On days 1, 11, and 22 of 1-dopa treatment, an abnormal involuntary movements (AIMs) test was performed to assess LID-like behavior in the animals. AIMs test was performed by monitoring animals at 20-minute intervals over a 3-hour period after a daily intraperitoneal 1-dopa injection. Animals were scored based on axial, orolingual, and limb AIMs on a severity scale of 0–4 as described elsewhere.25 AIMs scores in each of the 3 categories for each animal were summed for each session as the total AIMs score. Animals expressing AIMs scores ≥2 of 3 categories by day 22 were classified as LID animals.

Confocal Microscopy
Confocal laser scanning microscopy was performed using a Zeiss LSM 880 microscope with the accompanying ZEN software package (for detailed setup, see Supplementary Methods). Endothelial cell proliferation is the first stage of vascular sprouting, and histologic confirmation of an increase in BrdU-labeled endothelial cells is an indicator of angiogenesis.26 From each image, angiogenesis was assessed by counting the number of proliferating endothelial cell-labeled vessels per mm² of tissue. Proliferating endothelial cells were identified as BrdU-labeled nuclei with a characteristic flattened shape occurring within the RECA1-labeled vessel. The difference in the number of colocalizations between the lesioned and non-lesioned hemispheres was used to determine differences in angiogenesis on the lesioned hemisphere.

Imaging of the TH immunolabeled tissue was performed using Zeiss Apotome 2 microscope using the 20× objective. Tile-scan was used to capture the entire slice. From these images, dopaminergic lesion status was assessed by the number of immunoreactive cell bodies in the SN of the lesioned hemisphere compared to the unlesioned one. Animals with <90% dopaminergic cell loss in the lesioned hemisphere were excluded from the study due to incomplete dopaminergic lesion.

TPLSM and Dodt Gradient Imaging
The protocol for preparing tissue for imaging of striatal brain slices can be found in the Supplementary Methods. TPLSM imaging scans were performed using a Ti-sapphire laser with an excitation wavelength of 800 nm and 700 nm/100 ms laser pulse. The edge of the lumen could be identified beneath the thick smooth muscle layer of the arterioles, which was clearly observed in the Dodt scans. After the first 2 minutes of artificial cerebrospinal fluid (aCSF) perfusion (baseline), DA (dopamine hydrochloride; sigma H8502; 500 nM) diluted in aCSF was perfused (2 mL/min). During DA perfusion, the total volume in the recording chamber was consistently set to 1 mL. If there was a measurable widening (≥5%) in the distance between the 2 opposing parallel sides of the vascular lumen, the response was considered as vasodilation. If narrowing in the distance is observed, it was considered as vasoconstriction. If the percentage changes in the distance between the 2 sides is negligible (<5% from the baseline) for 10 minutes of recording time, it was considered as an unchanged response.

Twenty rats at postnatal day (21–28; “juvenile rats”) were used to examine astrocytic calcium dynamics and vessel diameter changes using TPLSM (for details, see Supplementary Methods). To examine the potential differences in different DA dose effect, we have tested 2 different DA concentrations at 500 nM (18 slices) and 20 μM (15 slices). Isolectin B4 labels the outer layer of the basement membrane, and thus the vessel diameter was measured on the outer boundaries of the arterioles. The emitted signal was obtained by photomultiplier tubes at 488 nm (isolectin B4) and 580 nm (rhod-2). Recorded images were analyzed every 3 seconds using Prairie View software (Bruker) to determine vessel lumen diameter. Changes in astrocytic calcium were determined by measuring rhod-2 Ca²⁺ fluorescence intensity changes, which was quantified by measuring the mean value of a manually selected somatic area of astrocytes using ImageJ software.

Statistical Analysis
All statistical analysis was performed in IBM SPSS 25 software (IBM Corp., Armonk, NY). Differences in angiogenesis between groups were assessed using 2 × 4 repeat measures ANOVA for hemisphere (contralateral and ipsilateral to lesioned side) and group (saline control, 2 mg/kg/day 1-dopa with no LID, 2 mg/kg/day 1-dopa with LID, and 10 mg/kg/day 1-dopa). Between groups, comparisons were performed using Tukey’s honest significant difference post-hoc test. A χ² test was used to examine the frequency of vasodilation, vasoconstriction, and unchanged vessel responses after DA perfusion across different groups (LID, non-LID, PD control, and wild-type [WT] control). One-way ANOVA was used to test if the summed vasomotor changes (regardless of direction) induced by DA were different across groups, followed by post-hoc Tukey test. In the juvenile rat experiments, unpaired t-test was used to investigate the effect of 2 different doses of DA on the maximum vasomotor responses. Results were considered statistically significant at P < 0.05.
Results
Dopaminergic Lesion and Behavioral Tests of LID Rat Model

We confirmed that all 6-OHDA-lesioned animals passed cylinder test (>60% forelimb asymmetry; 68.92 ± 14.42, data not shown). Abnormal involuntary movements test were used to quantify LID-like behaviors. In the 10 mg/kg L-dopa group, 5 of 5 animals developed LID. Out of the 45 animals in the 2 mg/kg treatment group, 17 animals developed dyskinesia symptoms, whereas 28 animals failed to develop dyskinesia within the 22 days. Two of 64 animals that passed cylinder test (>60% forelimb asymmetry) showed incomplete lesion and thus were excluded from the statistical analysis. There was no significant difference between lesion size between groups subsequently administered 2 mg/kg (LID and non-LID) or 10 mg/kg L-dopa \( F[2,34] = 0.807, P = 0.456 \) (Fig. 1B). Figure 1C shows the sum of AIMs scores on each day of L-dopa treatment between each treatment group. Both the 10 mg/kg and the 2 mg/kg LID groups progress over time, however, the 10 mg/kg group had strong AIMs scores beginning from day 1 \( (P < 0.001) \), whereas the 2 mg/kg LID group did not have any AIMs symptoms beginning on treatment day 1. [Color figure can be viewed at wileyonlinelibrary.com]

\[ \text{VASOMOTOR RESPONSE TO DA IS ALTERED IN LID} \]
Angiogenesis Is Affected by High Dose but Not Low Dose L-dopa

To histologically evaluate angiogenesis in the striatum and the SN, we co-labeled BrdU-positive cells (indicating proliferating cells) with RECA1, a marker of endothelial cells. We counted the number of BrdU-labeled nuclei (indicating proliferating cells) within the endothelial wall. In both the striatum and the SN, there was significant interaction effect between group and hemisphere ($F[3,18] = 8.193$, $P = 0.001$ and $F[3,18] = 9.586$, $P = 0.001$, respectively) (Fig. 2). We found in the 10 mg/kg group, there was about a 2-fold increase in the number of BrdU-RECA1 colocalizations in the striatum and SN of the lesioned hemisphere compared to the unlesioned hemisphere ($P < 0.001$). However, there was no significant evidence of angiogenesis in the LID animals with 2 mg/kg/day L-dopa in either the striatum or substantia nigra ($P = 0.737$ and $P = 0.927$, respectively). Between groups comparison revealed that when 2 mg/kg L-dopa dose is used, LID and non-LID animals could not be differentiated on the basis of angiogenesis in either the striatum or SN ($P = 0.992$ and $P = 0.945$, respectively).

The Dopamine-Induced Vasomotor Response in Rat Model of L-dopa-Induced Dyskinesia

To evaluate the effect of dopamine on vasomotor response, we used ex vivo microscopy to image both vasodilation and vasoconstriction evoked by DA perfusion (500 nM) in the arterioles of rat striatal brain slices. Figure 3 shows examples of vasoconstriction and vasodilation in response to DA application were observed using Dodt gradient contrast imaging (Supplementary Videos S1 and S2, respectively). The DA-induced vasomotor responses of all groups are represented in Figure 4A, whereas the statistical comparison between different conditions are summarized in Supplementary Data Table S2. The percentage of
observed arterioles showing vasodilation (43%) and vasoconstriction (48%) response to DA was almost equal in the brain slices of WT control rats. This trend was not significantly altered by 6-OHDA lesion (PD control) in either side (lesioned and unlesioned, $P > 0.6$, $\chi^2$). No hemispheric difference ($P = 0.8$, $\chi^2$) was observed in lesioned animals without L-dopa treatment. In the lesioned plus 2 mg/kg L-dopa animals, significantly altered DA-induced vasomotor response was not observed in non-LID rats in either hemisphere. However, the DA-induced vasomotor response in the LID rats was significantly shifted toward vasodilation (68% of observed arterioles) in the lesioned side compared to the unlesioned side ($P < 0.001$, $\chi^2$), which was significantly different from WT control rats ($P = 0.048$, $\chi^2$). The time course of vessel diameter changes is visualized in Figure 4B–4E for the different groups. No distinct hemispheric differences were observed in PD control rats nor non-LID (Fig. 4C,D). However, in the LID animals, DA application induced an increase in vasodilation in the lesioned hemisphere compared to the unlesioned side in the LID rats (Fig. 4E). There was no significant difference in the summed vasomotor changes in the unlesioned side across all groups ($F_{[3,88]} = 0.4926$, $P = 0.6883$, one-way ANOVA). However, in the lesioned side, there was a significant group effect ($F_{[3,112]} = 2.968$, $P = 0.035$, one-way ANOVA) with a significantly larger vasodilation in the LID versus non-LID animals ($P = 0.032$, post-hoc Tukey test) (Fig. 4F). Therefore, dopamine-induced vasodilatory responses were exaggerated only in rats that showed LID-like signs compared to non-LID animals and controls.

Dopamine Induced Astrocytic Control Over Striatal Vessel Diameter

We used 2-photon laser scanning microscopy to examine changes in arteriole diameter and astrocytic calcium

![Images](attachment://image.png)
signaling in brain slices of juvenile rats. Applying DA resulted in a balance between vasodilation and vasoconstriction responses in striatal arterioles in the juvenile animal brain slices. An example of decreased astrocytic Ca\(^{2+}\) level (Rhod-2, AM) and widened striatal arteriole (isolectin B4) is shown after DA perfusion (Fig. 5A; see Supplementary Video S3). Interestingly, we found that the vasodilation was preceded by a decrease in Ca\(^{2+}\) in the neighboring astrocytes (Fig. 5B). Among the striatal slices that showed vasodilation, significantly larger vasodilation was observed with 20 µM DA dose compared to the 500 nM group (t [10] = 2.460, P = 0.034). Similar phenomena were observed among the striatal slices that showed DA-induced vasoconstriction. In contrast, we observed that the vasoconstriction was preceded by an increase in Ca\(^{2+}\) in the neighboring astrocytes. An example of increased astrocytic Ca\(^{2+}\) level (Rhod-2, AM) and narrowed striatal arteriole (isolectin B4) is shown after DA perfusion (Fig. 5C,D; see Supplementary Video S4). Examining the time course of vasomotor changes and astrocyte Ca\(^{2+}\) signaling, it appears that vasoconstriction was always preceded by an increase in the Ca\(^{2+}\) in the adjacent astrocytes (Fig. 5D). Applying different DA concentrations did not result in a different balance in the vasomotor response between vasoconstriction and vasodilation (39% vasodilation in 500 nM DA; 61% vasoconstriction in 500 nM DA; 40% vasodilation in 20 µM DA; 60% vasoconstriction in 20 µM DA). The degree of maximum vasodilation and vasoconstriction was significantly greater with a high DA dose (20 µM) groups compared to the low DA dose (500 nM) group (t [10] = 2.460, P = 0.034; t [16] = 2.841, P = 0.0116, Fig. 5E,F). We directly observed the dopamine-induced astrocytic Ca\(^{2+}\) activity in relation to these vasomotor changes in the striatum and showed that increases and decreases in astrocytic calcium dictate the subsequent vasoconstriction and vasodilation, respectively.

**Discussion**

We replicated the previous findings showing that chronic l-dopa treatment with 10 mg/kg-induced angiogenesis in the lesioned hemisphere of 6-OHDA rat model. However, when using the lower 2 mg/kg l-dopa dose, we found no difference in angiogenesis between the LID group and the stable l-dopa responding animals. This indicates that angiogenesis is not necessary for the induction of mild LID-like behaviors, but could nevertheless contribute or exacerbate LID symptoms in rats with more severe injury. However, an increased vasomotor response to l-dopa in the direction of arteriole...
vasodilation did differentiate LID and non-LID animals. This indicates that a key factor in the neurovascular uncoupling response in LID is an increased sensitivity of the vasodilatory response. Additionally, in juvenile rat brain slices, we found that the direction of striatal vasomotor responses (vasodilation vs. vasoconstriction) is dictated by preceding perivascular astrocytic Ca\(^{2+}\) level changes (decreasing vs. increasing, respectively), indicating a potential role of glial dopaminergic system in vascular abnormality associated with LID.\(^{27-32}\)

Previous perfusion imaging studies in humans have shown an increase in striatal blood flow in LID patients in response to L-dopa treatment much more than non-LID patients\(^{11,32}\) and in rat models with toxin-induced parkinsonism.\(^{12}\) The increased blood flow was normalized when medication was withdrawn, which indicates that there is a change in the vasomotor response regulated by astrocytes and endothelial smooth muscle, rather than a static change in the microvascular architecture.\(^{11}\) Our results are in line with this, because we directly observed an increase in arteriole diameter in striatal brain slices of LID animals when DA was applied. The prevalence of vasomotor alterations in LID patients and animal models observed with multiple modalities leads us to speculate on the role of these alterations in dyskinesia symptoms. If dopaminergic signaling in LID subjects causes an increase in striatal CBF, this would result in greater L-dopa delivery through the blood supply. Importantly, the blood–brain barrier is disrupted in PD, even

---

**FIG. 5.** The vasodilation induced by DA is accompanied with calcium reductions in perivascular astrocytes, whereas vasoconstrictive response to DA is corresponded with calcium increases in juvenile rat (21–28 postnatal days) striatal slices. Representative TPLSM images of calcium (red, Rhod 2) in perivascular astrocytes (white arrow) and triggered arteriolar (green, isolectin B4) vasodilation (yellow arrow) (A) and vasoconstriction (C) are shown before and after DA. The percentage changes in astrocytes Ca\(^{2+}\) signaling (green) and arteriole diameter (red) before and after DA during vasodilation (B) and vasoconstriction (D). Dose-dependent effect of DA (500 nM and 20 μM concentrations) on the maximum observed increase (E) and decrease (F) in vessel diameter. Data are presented as mean ± SD. [Color figure can be viewed at wileyonlinelibrary.com]
independently of apparent angiogenesis, and may be particularly disrupted in LID subjects. Increased cerebral blood flow could therefore result in greater unregulated l-dopa transmission into the striatal microenvironment, resulting in increased DA flux responsible for LID symptoms, as well as further reinforcing astrocyte-mediated CBF increases in a positive feedback loop.

In our ex vivo analysis of vessel diameter changes using Dodt gradient imaging, we found that DA appears to produce both a vasodilatory and vasoconstrictive effect on striatal arterioles, which is consistent with the bimodal vasoactive effect of dopamine described elsewhere, which mimics the opposite effects of D1/D5 (excitatory) versus D2/D3 (inhibitory) on the neuronal activities. In the non-LID or saline-treated rats, DA at 500 nM concentration induced an approximately equal number of vasodilatory and vasoconstrictive responses, potentially via the balanced D1-like versus D2-like receptor activation. However, in the LID animals, this balance is shifted toward vasodilation resulting in increased CBF.

Changes in the astrocytic reaction to DA may underlie this shift in the vasomotor response in LID animals. This is supported by our observation that in juvenile rat brain slices, dopamine-induced vasomotor response was always preceded by intracellular calcium signaling in the perivascular astrocytes. One limitation of this study is that we were not able to investigate this in adult parkinsonian animals due to the toxicity of the Rhodamine dye making the adult brain slices unviable. However, our findings in juvenile animals may be a useful hypothesis generating result, as it shows astrocytic calcium-dependent dopamine signaling pathways are relevant to CBF alterations. Dopamine-induced calcium increases and decreases in astrocytes are dependent on the type of dopamine receptor involved, with calcium increases requiring both D1-like and D2-like receptors, whereas calcium decreases involve D2/D3 receptors only. Dopamine-dependent increases in astroglial calcium levels are dependent on IP3-related intracellular calcium signaling mechanisms that are induced by dopaminergic pathways directly through interaction between D1 receptor and phospholipase C, or through D1-dependent modulation of intracellular NADH signaling. Astrogial calcium decreases could occur through the modulation of voltage-gated ion channels, which astroglia express functional copies of. Interestingly, activation of D2/D3 receptors in the nucleus accumbens of rats has been shown to modulate the activity of L-type voltage-gated ion channels, reducing calcium levels. Therefore, an increase in astrocytic D2/D3 expression in the striatum could be relevant to cerebral blood flow changes in LID, although further research on this topic is warranted.

Although we only investigated changes in arteriole diameter in the regulation of vertebral blood flow, capillary pericytes are also known to be an important component of neurovascular coupling. Dopaminergic axons have been shown to innervate both endothelial smooth muscle as well as capillary pericytes, and therefore may directly affect local cortical blood flow.

The present study used a 2 mg/kg l-dopa dose delivered subcutaneously once daily, which is a lower dose than much of the previous literature that typically use 6–10 mg/kg doses. Our rationale for using a lower dose was to produce a split in LID versus non-LID animals for the purposes of comparing differences between these 2 groups. In contrast with our results, a previous study has indicated that 2 mg/kg l-dopa induces negligible AIMs symptoms in 6-OHDA rats. However, the longer treatment period in our study (22 days vs. 15 days) could be responsible for this discrepancy.

In conclusion, we show that an aberrant vasomotor response mediated by perivascular astrocytes characterizes dyskinesia symptoms in a Parkinsonian rat model. This response could play an important role LID by increasing the unregulated DA transmission in the stratum which underpins dyskinesia symptoms.
VASOMOTOR RESPONSE TO DA IS ALTERED IN LID

10. Muñoz A, Garrido-Gil P, Dominguez-Mejide A, Labandeira-Garcia JL. Angiotensin type 1 receptor blockade reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson’s disease. Involvement of vascular endothelial growth factor and interleukin-1β. Exp Neurol 2014;261:720–732.

11. Hirano S, Asanuma K, Ma Y, Tang C, Feigin A, Dhawan V, et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson’s disease. J Neurosci 2008;28:4201–4209.

12. Lerner RP, Bimpisidis Z, Agorastos S, Scherrer S, Dewey SL, Cenci MA, et al. Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model. Neurobiol Dis 2016;96:31–37.

13. Macvicar BA, Newman EA. Astrocyte regulation of blood flow in the brain. Cold Spring Harb Perspect Biol 2015;7:1–15.

14. Howarth C. The contribution of astrocytes to the regulation of cerebral blood flow. Front Neurosci 2014;8:1–9.

15. Choi JK, Chen YI, Humel E, Jenkins BG, Chen YI. Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses. Synapse 2009;63:764–772.

16. Ren J, Xu H, Choi JK, Jenkins BG, Chen YI. Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses. Synapse 2009;63:764–772.

17. Straub SV, Bonev AD, Wilkerson MK, Nelson MT. Dynamic inositol trisphosphate-mediated calcium signals within astrocytic endfeet underlie vasodilation of cerebral arterioles. J Gen Physiol 2006;128:659–669.

18. Mulligan SJ, Macvicar BA. Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. Nature 2004;431:195–199.

19. Kim KJ, Iddings JA, Stern JE, Blanco VM, Croom D, Kiror SA, et al. Astrocyte contributions to flow-pressure-evoked paracrine arterial vasoconstriction. J Neurosci 2013;33:8243–8257.

20. Adachi YU, Yamada S, Satomoto M, Higuchi H, Watanabe K, et al. General anesthesia selectively disrupts astrocyte calcium signaling in the awake mouse cortex. Proc Natl Acad Sci U S A 2012;109:18974–18979.

21. Tsurugizawa T, Takahashi Y, Kato F. Distinct effects of isoflurane on basal BOLD signals in tissue/vascular microstructures in rats. Sci Rep 2014;4:6177.

22. Engelhard K, Werner C. The effects of general anesthetics and variations in hemodynamics on cerebral perfusion. Appl Cardiopulm Pathophysiol 2009;13:157–159.

23. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 2002;15:130–132.

24. Cenci MA, Lee CS, Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;10:2694–2706.

25. Irvin MW, Zijlstra A, Wikswo JP, Pozzi A. Techniques and assays for the study of angiogenesis. Exp Biol Med 2014;239:1476–1488.

26. Bal A, Bachelot T, Savasta M, Manier M, Verna JM, Benabid AL, et al. Evidence for dopamine D2 receptor mRNA expression by striatal astrocytes in culture: in situ hybridization and polymerase chain reaction studies. Mol Brain Res 1994;23:204–212.

27. Miyazaki A, Asamama M, Diaz-Corrales FJ, Miyoshi K, Ogawa N. Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Res 2004;1029:120–123.

28. Duffy AM, Fitzgerald ML, Chan J, Robinson DC, Milner TA, Mackie K, et al. Acetylcholine α7 nicotinic and dopamine D2 receptors are targeted to many of the postsynaptic dendrites and astrocytes in the rodent prefrontal cortex. Nat Neurosci 2011;15:1305–1307.

29. Cervetto C, Venturini A, Passalacqua M, Guidolin D, Genedani S, Fuxe K, et al. A2A-D2 receptor-receptor interaction modulates gliotransmitter release from striatal astrocyte processes. J Neurochem 2017;140:268–279.

30. Xin W, Schuebel KE, wing JK, Gimbio R, De Biasi LM, Stadil M, et al. Ventral midbrain astrocytes display disparate physiological features and sensitivity to dopamine D2 receptor signaling. Neuropsychopharmacology 2019;44:344–355.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.